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Background: The Gamma-glutamyl carboxylase (GGCX) gene, as with Vitamin K Epoxide Reductase Complex Sub-
unit 1(VKORC1), CytochromeP450 Complex Subunit 14 F2 (CYP4F2) and CytochromeP450 Complex Subunit2C9
(CYP2C9), is a candidate predictor for appropriate maintenance warfarin dose. However, the association between
GGCX gene polymorphisms and warfarin dose requirement is still controversial. To quantify the inﬂuence of
GGCX polymorphisms on warfarin dose requirements, we performed a systematic review and meta-analysis.
Methods: According to PRISRM statement (Preferred reporting items for systematic reviews and meta-analyses), a
comprehensive literature search was undertaken through August 2014 looking for eligible studies in Embase,
Pubmed,Web of Science and the Cochrane Library. The impact of GGCX polymorphisms on mean daily warfarin
dose (MDWD) was counted by means of Z test. RevMan 5.2.7 software (developed by the Cochrane Collaboration)
was applied to analyze the relationship between GGCX gene polymorphisms and warfarin dose requirements.
Results: Nineteen articles including 21 studies with a total of 6957 patients were included in the meta-analysis.
Among three investigated single nucleotide polymorphisms (SNPs), rs11676382 showed higher CC genotype
frequencies in Asian than those in Caucasian(97.7% vs. 86.9%); patients who were “G carriers” (that is, carried the
GGCX rs11676382 CG or GG genotypes) required 27% lower warfarin dose than CC genotype[95%Conﬁdence
Interval(CI) = 17%-37%, P= 0.000, I2%= 82.0 and PQ = 0.000], moreover, stratiﬁed analysis by ethnicity showed
similar results in Caucasian(23% lower, 95%CI = 12%-33%), but not in Asian. With respect to genetic variation of
rs699664 and rs121714145 SNPs, no signiﬁcant impact on warfarin dose requirements were demonstrated.
Conclusions: This meta-analysis suggested that GGCX rs11676382 polymorphismmay be one of factors affecting the
dose of warfarin requirement, and the effects are different in different ethnicities. Further studies about this topic in
different ethnicities with larger samples are expected to be conducted to validate our results.© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Warfarin is commonly used in clinical treatment of various disorders,
especially thromboembolic disease. The narrow therapeutic range of
warfarin dosage may increase the risk of recurrence of thromboembo-
lism and bleeding [1], so it is difﬁcult to establish the appropriate dose
of warfarin to achieve anticoagulation. Over time, many factors have
proven to be associated with therapeutic warfarin dose requirements,
including basic elements such as gender, age, weight, and body surface86 771 5353342.
wuzhitong@126.com (Z. Wu),
), 54963242@qq.com (T. Li),
g), junqiangchen8@163.com
the article, so they should be
. This is an open access article underarea [2–4]; however, these elements do not explain all of the differences
that currently exist among warfarin dose requirements among different
individuals and different ethnicities.
In recent years, it has been shown that the genetic variability of the
pharmacokinetics and pharmacodynamics of warfarin may be important
in determining the individual and interethnic differences in appropriate
warfarin dosage [5–9]. VKORC1, CYP4F2, and CYP2C9 polymorphisms
contribute to inter-populationdifference inwarfarin doses amongdiverse
geographic regions [5,7,8]. GGCX, as a key cofactor for the activation of
clotting factors (VII, IX, X) to reduce Vitamin K [10], is also a possible
candidate, given that recent studies have found a signiﬁcant relationship
between GGCX genotype and warfarin dose [11–18].
The association between GGCX SNPs polymorphisms and warfarin
dose requirements is biologically plausible. The GGCX gene, located on
chromosome 2p12 in humans and consisting of 15 exons, plays the crit-
ical pharmacodynamic role in the generation of vitamin K-dependentthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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by reducing vitamin K to vitamin K-2, 3-epoxide [19]. In addition, GGCX-
knockout mice die at birth from massive hemorrhage [20]. Crosier et al.
[21] found that GGCX SNPs showed signiﬁcant associations with percent
undercarbosylated osteocalcin, a measure of vitamin K-dependent car-
boxylation in extra-hepatic proteins, which would inﬂuence warfarin
dose requirements in order to achieve stable oral anticoagulation.
For the past decades, a number of studies on the relationship between
GGCX gene and warfarin dose requirement had been reported [11–18,
22–30]. These studies provide certain evidences that the genotype-
based dose predictionsmay in future enable personalised drug treatment
from the start of warfarin therapy. In those studies, the rs699664 SNP in
exon 8, rs12714145 SNP in intron 2, and rs11676382 SNP in intron 14
were the most researched SNPs. However, variant GGCX alleles have
been associated with warfarin dosing in some studies with different
ethnicities [12,23,31], but have not been consistently replicated in other
studies [32,33]. Therefore, it is necessary to substantiate or validate the
impact of GGCX polymorphisms in patients taking warfarin. The aim of
this study was to quantify the effects of individual GGCX genotype on
warfarin dose requirements, by means of a systematic literature review
and meta-analysis.
Materials and Methods
This meta-analysis was conducted according to PRISMA statement
(Preferred reporting items for systematic reviews and meta-analyses),
including search strategy, selection criteria,data extraction and data
analysis [34].
Identiﬁcation of Eligible Studies
We used the following search terms: “Gamma-glutamyl carboxyl-
ase” or “GGCX” in combination with “polymorphism,” “mutation,” or
“variant” in combination with “warfarin,” in Embase, PubMed, Web of
Science and the Cochrane Library up to Aug, 2014. Two investigators
(YFS and LS) conducted an extensive literature search independently
for all publications. There was no language restriction. Articles in refer-
ence lists were also hand-searched. Only human studies were searched.
Inclusion and Exclusion Criteria
The following criteria were used to choose suitable studies:
(1) The following GGCX gene SNPs was studied: rs699664 (G8016A,
c.974GNA), rs12714145 (c.214+597GNA, 3261GNA), rs11676382
(12970CNG);
(2) Studies offering information regarding the number of genotypes,
the maintenance dose of warfarin (mean with either standard
deviation or 95% conﬁdence interval) separately for GGCX
genotype groups.
Publications were excluded from the meta-analysis if:
(1) Review articles, letters, case reports, editorials, and conference
abstracts.
(2) The articles did not include genotype frequencies orwarfarin dose,
and this informationwas not available from the authors contacted.
Data Extraction
Two investigators (YFS and LS) independently extracted data from
the included studies. The recorded data mainly included genotype
frequencies of GGCX and warfarin dose (mean, SD) for each genotype.
Also extracted from the eligible studies was basic information including
theﬁrst author’s name, publication date, country, ethnicity, indication ofwarfarin, total sample size (male, female), mean age of sample, target
value of international normalized ratio (INR), and genotyping method.
Accuracy of the extracted information was veriﬁed by ensuring that
the data recorded by the 2 investigatorsmatches; if it did not, the inves-
tigators rechecked the data extracted. If the two investigators could not
reach an agreement, the disputewas submitted to a third reviewer (QX)
to decide.
Quality Score Assessment
The quality of the selected studies was independently assessed by
two investigators (CL and YFS) independently following the criteria
predeﬁned by Little et al. [35]. These quality criteria were based on:
(1) analytic validity of genotyping (genotyping method, quality control
measures, timing of sample collection and analysis, and types of sam-
ples used); (2) selection of study subjects (geographic area recruitment
period, exclusion criteria for cases and controls, mean age and standard
deviation or age range of study subjects, and distribution by sex);
(3) confounding factors, including population stratiﬁcation (potential
correlation of the genotype identiﬁed and taken into consideration in
design or analysis); and (4) statistical issues (method of analysis used
in reference, and software used to perform the analysis). If most of the
above criteria were satisﬁed, a study was graded as “++”. A study
that fulﬁlled some of the criteria would be graded as “+”; few or no
criteria fulﬁlled resulted in a grade of “-” [35].
Statistical Analysis
To remove any heterogeneity caused by deviation in warfarin phar-
macokinetics and pharmacodynamics sensitivity among different study
populations, in our meta-analysis, themaintenance of warfarin dose for
each GGCX genotype group was normalized using the homozygous
wild-type group as a reference. The normalization procedure was
performed by dividing themean dose and associated standard deviations
in each group by the mean maintenance dose in the GGCX reference
group [36].
For the GGCX rs699664 and rs12714145, we deﬁned carriers of AG or
AA genotype as “A carriers”, A carriers (AG+AA), AA and AG were com-
pared with GG genotype (reference group).With respect to GGCX
rs11676382, CG or GG genotype were deﬁned as “G carriers”, because
GG frequencieswere too small, only G carriers (CG+GG)were compared
with CC genotype (reference group). The calculated mean differences
represent relative rather than absolute differences in maintenance
dose; in other words, a mean difference of 0.5 would indicate a 50%
increase in warfarin dose requirement [36].
Theweight is the inverse of its standarddifferences ofwarfarin dose in
each study, and the effect of each GGCX genotype on warfarin dose was
deﬁned as mean difference (MD), which was calculated by subtracting
the normalized mean warfarin dose for the respective genotypes from
the reference. TheWeightMeanDifference (WMD)was used as indicator
of effect, whichwas calculated bymultiplying theMD and relatedweight
of each study. Each study’sWMDwas summed to arrive at the totalWMD
[31]. The impact ofGGCX SNPs onmeandailywarfarin dose (MDWD)was
counted by means of Z test; a P value b0.05 was considered statistically
signiﬁcant. Heterogeneity was assessed by a chi-squared Q test and I-
squared statistics, as has been previously described in the literature [37,
38]. If PQ b 0.1 or I2 N 50%, we considered the heterogeneity signiﬁcant,
and a random-effects model was conducted using the DerSimonian and
Laird method. Otherwise, a ﬁxed-effects model (the Mantel-Haenszel
method) was used. Stratiﬁed analysis was carried out by ethnicity and
the mean target INR. We deﬁned the mean target INR b 2.5 and
INR ⩾ 2.5 as two separated subgroups.
Sensitivity analyseswere carried out by excluding studies one by one,
especially excluded study with low quality or small sample size. Begg’s
funnel plot and Egger’s test were used to investigate the publication
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cally signiﬁcant.
All the tests in this meta-analysis were conducted with RevMan 5.2.7
(Cochrane Collaboration) and STATA software (version 12.0; Stata
Corporation, College Station, Texas, USA).
Results
Literature Selection and Study Characteristics
Fig. 1 shows the ﬂow of selecting studies. According to the inclusion
and exclusion criteria, 19 articles including 21 studies in 143 candidate
publicationswere included in themeta-analysis. A total of 6957 patients
were included between 2005 and 2014,of which 3552 patients for
rs6996694, 1842 patients for rs11676382 and 1771 patients for
rs12714145. Eleven eligible studies referred to the presence of the
GGCX rs6996694 polymorphism [11–16,22,23,25], ﬁve for rs11676382
[18,23,26–28] and ﬁve for rs12714145 [3,17,18,22,29]. The articles by
Schelleman H et al. [23] and Cavallari L et al. [3] were separated as
different studies because they included two ethnicities and two SNPs
respectively. Most of the studies are from Asian [12–17,22,25–27];
two studies from USA [18,23]. The main indications of warfarin are for
use during heart valve replacement (HVR), deep vein thrombosis
(DVT), atrial ﬁbrillation (AF), pulmonary embolism (PE), and ischemic
stroke. All studies except Schelleman H et al. [23] were graded as
“++” during the quality score assessment; one article in Chinese [25]Fig. 1. Flow diagram of included sand the others were published in English. The characteristics of the
included studies are shown in Table 1.Allele Frequencies in Different Ethnicities
GGCX gene frequencies and warfarin dose requirements are shown
in Table 1. On average, the GGCX rs699664 frequencies of GG, GA and
AA were 46.0%, 44.7%, and 9.3% for Asian, and 45.6%, 46.3% and 8.1%
for Caucasian. No statistically signiﬁcant difference was shown between
the two ethnicities (χ2 = 0.296, P = 0.863). Similar results were
showed in G allele vs. A allele model (χ2 = 0.021, P= 0.884).However,
the frequencies of GG, GA andAA in African Americanwere 20.9%, 44.3%
and 34.8% respectively, which was signiﬁcant difference with the other
two ethnicities(χ2 = 158.98, P= 0.000).
For the GGCX rs11676382, genotype and allele frequencies of this site
showed signiﬁcant difference among Asian and Caucasian population
(P= 0.000).The Asian population have a higher CC frequency than that
of Caucasian group (97.7% vs. 86.9%).There was no GG genotype reported
in Asian population.
With respect to GGCX rs12714145, signiﬁcant difference was showed
in genotype frequencies comparison (χ2 = 17.770, P = 0.000) in
Caucasian and Asian, but not in allele frequencies comparison, and
the Caucasian population have a higher GG frequency than that of
Asian population (46.5% vs. 36.7%). However, the frequencies of GG,
GA and AA in African American were similar with Asian populationtudies for this meta-analysis.
Table 1
The characteristics of the included studies.









(mean ± SD, md/day)
Quality
score
rs699664 GG GA AA GG GA AA
Loebstein,R 2005 Israel Caucasian 100(52) 62.0 HV,AF, DVT,PT 2.7 ± 0.5 50.0 41.0 9.0 5.50 ± 1.80 5.8 ± 1.90 5.14 ± 2.00 ++
Kimura R 2007 Japan Asian 93(71) 68.1 ± 10.0 Stoke 1.6-2.6 51.6 41.9 6.5 3.25 ± 1.19 2.63 ± 0.77 2.79 ± 1.07 ++
Ohno M 2009 Japan Asian 125(60) 73.1 ± 11.6 AF,DVT, PE 1.5-3.0 54.4 37.6 8.0 2.86 ± 1.26 2.49 ± 1.24 2.15 ± 1.11 ++
Liu Y 2010 China Asian 794(43) 46.8 ± 11.9 HV 1.8-3.0 45.3 45.7 8.9 1.54 ± 1.18 1.55 ± 1.05 1.61 ± 1.11 ++
Choi JR 2011 Korean Asian 564(54) 63.2 ± 11.7 HVR,AF,DVT,PT 2.1 ± 0.8 47.0 44.3 8.7 3.50 ± 2.00 3.00 ± 1.80 3.00 ± 2.00 ++
SL Zhong 2012 China Asian 841(42) 51.3 ± 7.5 HVR,AF,DVT 1.8-3.0 45.5 45.5 8.9 3.00 ± 1.67 2.90 ± 1.67 2.90 ± 1.67 ++
Schelleman 2010 USA African
American
22 N/A N/A 2.0-3.0 9.1 45.5 45.5 6.96 ± 1.13 6.61 ± 2.49 5.71 ± 2.38 +
Caucasian 36 N/A N/A 2.0-3.0 33.3 61.1 5.6 5.80 ± 2.57 5.25 ± 2.17 5.19 ± 1.29 +
Lou Y 2012 China Asian 488(44.7) 56.7 ± 12.1 HVR,AF,DVT,PT 1.8-2.5 45.5 42.0 12.5 3.65 ± 1.52 3.37 ± 1.36 3.63 ± 1.24 ++
Liang Y 2013 China Asian 280(46.0) 47.9 ± 12.5 N/A 1.5–3.0 42.5 48.9 8.5 3.09 ± 1.04 3.46 ± 1.24 3.51 ± 1.44 ++
Cavallari L 2013 USA African
American
208 58 ± 16 N/A 3.0 22.1 44.2 33.7 5.88 ± 0.74 5.98 ± 0.79 6.20 ± 1.22 ++
rs11676382 CC CG GG CC CG GG
Krishna 2014 Indian Asian 240(36.7) 43.3 ± 11.2 HVR,AF,DVT 3.0–3.5 97.9 2.1 - 4.8 ± 2.20 2.6 ± 0.50 N/A ++
King CR 2010 USA Caucasian 985(50.7) 60 (15) N/A 2.3 (0.4) 88.6 11.2 0.2 4.9 ± 1.60 4.1 ± 1.60 3.8 ± 2.20 ++
Rathore SS 2014 Indian Asian 225(67.1) 37.7 ± 1.3 VT 20.-3.5 94.2 4.9 0.9 0.056 (0.023)⁎ 0.053 (0.024)⁎ N/A ++
Wypasek E 2014 Poland Caucasian 479(53) 48.8 ± 14.7 N/A 2.0-3.0 84.3 14.8 0.9 47.8 ± 8.79# 33.87 ± 3.67# ++
Schelleman 2010 USA Caucasian 36 N/A N/A 2.0-3.0 88.9 11.1 N/A 46.5 ± 23.06# 38.3 ± 4.73# N/A +
rs121714145 GG GA AA GG GA AA
Liang Y 2013 China Asian 283(46.0) 47.9 ± 12.5 N/A 1.5–3.0 36.7 51.6 11.7 3.20 ± 1.02 3.39 ± 1.25 3.35 ± 1.35 ++
Huang SW 2010 China Asian 217(41.5) 51.3 (15.0) HVR,AF,DVT 1.8–3.0 38.7 53.9 7.3 2.69 ± 1.07 2.91 ± 1.16 3.39 ± 1.40 ++
Geisen C 2011 Germany Caucasian 75(49.3) 64 (19–92) HVR,AF,VT 2.0–3.0 34.7 45.3 20.0 2.14 ± 0.28 2.16 ± 0.39 2.33 ± 0.46 ++
King CR 2010 USA Caucasian 985(50.7) 60 (15) N/A 2.3 (0.4) 47.7 41.1 11.7 5.1 ± 1.60 4.7 ± 1.60 4.7 ± 1.60 ++
Cavallari L 2013 USA African
American
211 58 ± 16 — 3.0 33.6 50.7 15.6 5.88 ± 0.84 5.93 ± 1.02 5.90 ± 0.92
AF, Atrial Fibrillation; HVR, Heart Valve Replacement; MI, Myocardial Infarction; DVT, Deep Vein Thrombosis; PVR, Prosthetic Valve Replace; PE, Pulmonary Embolism; N/A, no data.
++, High score; +, Low score.
⁎ mean daily dose, mg/kg body weight (SD).
# Warfarin dose (mean ± SD, md/week).
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American, respectively)
Meta Analyses Results
Impact of GGCX rs699664 on MDWD
The inﬂuence of GGCX rs699664 polymorphism on warfarin dose
requirement is shown in Fig. 2. The total number of patients carrying
AA, AG and GGwere 367, 1476 and 1511, respectively.When compared
to individualswith thehomozygousGGgenotype, all comparisonmodel
showed no signiﬁcant impact on warfarin dose requirements. Stratiﬁed
analysis by ethnicity and mean target INR showed similar results with
the overall analysis (Table 2).
Impact of GGCX rs12714145 on MDWD
The inﬂuence of GGCX rs12714145 on warfarin dose requirement is
shown in Fig. 3. The total number of patients carrying AA, AG and GG
were 252, 807 and 752, respectively. The impact of rs12714145 on
MDWD were similar to rs699664 and no signiﬁcant difference was
found in overall analysis. Only the analysis of AA vs. AG shows homoge-
neity (I2% = 0.0 and PQ = 0.500 for heterogeneity) and a ﬁxed-effects
model was used, however, the other comparison models were all used
random-effects model. Stratiﬁed analysis by ethnicity and mean
target INR showed similar results with the overall analysis, however,
the AA+AG vs. GG comparison model showed an decreased effect in
Caucasian population, but opposite effect for Asian (Table 2).
Impact of GGCX rs11676382 on MDWD
The inﬂuence of GGCX rs11676382 on warfarin dose requirement is
shown in Fig. 4. The total number of patients carrying CC, CG and GGwere 1638, 1930 and 11, respectively. However, because the GG geno-
type frequencies of the rs11676382 variant was below 5%, this meta-
analysis only performed a CG+GG vs. GG comparison model. Analysis
showed statistical heterogeneity in this comparison model (I2 = 82%
and PQ = 0.000), hence a random-effects model was used. The result
provided an evidence that G allele carriers required 27% (P = 0.000,
95%CI = 22%-33%) lower MDWD than that of CC genotype. Stratiﬁed
analysis by ethnicity and mean target INR showed showed similar
results in Caucasian group (23% lower, P = 0.000, 95%CI = 12%-33%,
I2 = 84% and PQ = 0.002 for heterogeneity), INR b 2.5 group (17%
lower, P = 0.000, 95%CI = 11%-23%, only one study) and INR ⩾ 2.5
group (31% lower, P = 0.000, 95%CI = 18%-44%, I2 = 75% and PQ =
0.008 for heterogeneity) using random-effects model, but not in Asian
subgroup (P= 0.270) (Table 2).
Subgroup Analysis
Considering the inﬂuence of ethnicity on warfarin dosage require-
ment and the main determinant of warfarin dose adjustment is the
value of INR, we also performed a stratiﬁed analysis by ethnicity and
the mean target INR (Table 2). No statistically signiﬁcant results hap-
pened in Asian group in all analysis, yet, with respect to rs11676382,
G allele carriers showed 23% (P = 0.000, 95%CI = 12%-33%) lower
warfarin dose requirement than CC genotype in Caucasian group. The
results of stratiﬁed analysis according to the mean target INR were
similar with the overall analysis and stratiﬁed analysis by ethnicity.
Sensitivity Analysis and Publication Bias
Sensitivity analysis was carried out by excluding each study one
at a time. Further sensitivity analysis was performed by excluding
the study of Schelleman H et al. [23], in which the sample is obvi-
ously smaller than that in other studies, moreover, the study was
Fig. 2. Forest plots of impact ofGGCX gene rs699664 polymorphism onwarfarin dose requirement.A: AA vs. GG carriers, B: AG vs. GG carriers, C: A carriers (AA+AG) vs. GG carriers,D: AA
vs. AG carriers. Mean (SD): mean and standard deviation of normalized warfarin doses associated with each genotype. CI: conﬁdence interval.
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did not ﬁnd that this analysis revealed any signiﬁcant change or
revision in ﬁndings.We also performed a stratiﬁed analysis by ethnicity (Table 2). No
statistically signiﬁcant results happened in Asian group in all analysis,
yet, with respect to rs11676382, G allele carriers showed 23% (P =
Table 2
Stratiﬁed analysis by ethnicity and mean target INR.
Comparison models overall Ethnicities Mean INR
Caucasian Asian African-American INR b 2.5 INR ⩾ 2.5
rs699664
AA vs. GG 0[-4,4] -8[-3,14] -3[-9,3] -1[-22,19] -3[-9,3] 3[-3,9]
AG vs. GG -4[-9,2] 3[-10,16] -6[-13,2] 2[-3,6] -6[-13,2] 2[-2,6]
AA vs. AG 2[-2,6] -8[-29,12] 3[-3,9] 2[-3,8] 3[-3,9] 2[-4,7]
AA+AG vs. GG -4[-9,2] 1[-11,14] -5[-13,2] 3[-2,7] -5[-13,2] 2[-2,8]
rs12714145
AA vs. GG 2[-6,10] 0[-17,16] 10[-3,24] 0[-6,6] 4[-13,21] 2[-4,8]
AG vs. GG 1[-5,7] -4[-13,5] 7[0,14] 1[-4,6] 1[-10,13] 1[-3,5]
AA vs. AG 1[-3,5] 2[-4,7] 4[-10,17] -1[-7,5] 1[-5,7] 1[-5,7]
AA+AG vs. GG 1[-6,8] -7[-11,-4] 7[1,14] 1[-3,5] 2[-10,14] 1[-3,5]
rs11676382
CG+GG vs. CC -27[-37,-17] -23[-33,-12] -33[-70,5] N/A -17[-23,-11] -31[-44,-18]
Data were showed as weight mean difference [95% Conﬁdence Intervals].
-, reduction of warfarin dose requirement.
N/A, no data.
744 Y. Sun et al. / Thrombosis Research 135 (2015) 739–7470.000, 95%CI = 13%-33%) lower warfarin dose requirement than CC
genotype in Caucasian group.
Begg’s funnel plot and Egger’s linear regression test were also
conducted to investigate the publication bias; the results of eachFig. 3. Forest plots of impact ofGGCX gene rs12714145 polymorphism onwarfarin dose requireme
AG carriers. Mean (SD): mean and standard deviation of normalized warfarin doses associated wstudy’s genotype with respect to effect on warfarin dose reductions
against the inverse standard error showed that no signiﬁcant publi-
cation bias was detected in each compared model (All P N 0.05,
data not shown).nt.A: AA vs. GG carriers,B: AG vs. GG carriers, C: A carriers (AA+AG) vs. GG carriers,D: AA vs.
ith each genotype. CI: conﬁdence interval.
Fig. 4. Forest plots of impact ofGGCX gene rs11676382 polymorphism onwarfarin dose requirement. Only CG+GG vs. CCmodelwas carried out in this study because of fewGG genotype.
Mean (SD): mean and standard deviation of normalized warfarin doses associated with each genotype. CI: conﬁdence interval.
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In the current systematic review andmeta-analysis, our results indi-
cated that GGCX polymorphisms inﬂuence warfarin dose requirements.
The G carriers of the GGCX rs11676382 require warfarin dose that are
27% lower than that in carriers of CC genotype. However, no effects
were found in the genetic variants of the GGCX rs699664 and
rs12714145 SNPs. These results are based on data from almost
6957 patients, and the estimates are likely to be themost comprehensive
published to date.
Genetic variation has a clinically important impact on stable warfarin
dose. The association of CYP2C9 genotype andwarfarin dose requirement
has previously been investigated in a meta-analysis, which included
approximately 8000 patients, and demonstrated that that carriers of the
CYP2C9 *1/*2, *1/*3, *2/*2, *2/*3, and *3/*3 genotypes require warfarin
doses that are 19.6, 33.7, 36.0, 56.7, and 78.1% lower than in carriers of
the wild-type CYP2C9 *1/*1 genotype, respectively [36]. Yang et al. [31]
performed a meta-analysis based on 19 studies to investigate the impact
of VKORC1 gene polymophism onwarfarin dosage requirement, and their
results indicates that the VKORC1 1173CT and−1639GAheterozygosities
carriers required approximately 50% higher warfarin doses than 1173TT
and −1639AA homozygosities carriers. Caldwell et al. [7] also found
that patients with 2 TT alleles of CYP4F2 require approximately
1 mg/day more warfarin than patients with 2 CC alleles. However, it
has been found that polymorphisms of the above three genes, together
with clinical characters such as gender, age, weight and body surface
area, can only explain about 50% of the effect on warfarin dose require-
ment [7,39,40]. Therefore, other genetic variants, as this study suggested,
the GGCX polymorphism may be considered in warfarin-dosing algo-
rithms in predicting warfarin dose among different patients, although
our pooled analysis indicated that effect of GGCX polymorphisms was
lower than that of CYP2C9 and VKORC1 in terms of inﬂuencing warfarin
maintenance dose.
Over the past decades, the rs699664 loci is the most studied SNP of
GGCX, however, the importance of genetic polymorphisms of this SNP
on warfarin dose requirement is still controversial. Our meta-analysis
expanded the sample size and increasing the efﬁciency of statistical
tests, and found no signiﬁcant association betweenGGCX rs699664 poly-
morphism and warfarin dose requirement. Therefore, GGCX rs699664
polymorphism was not considered to affect individual warfarin dose
requirements. Actually, Only three studies examined the effect of a
subset ofGGCX rs699664 polymorphism onwarfarin dose in our system-
atic review, interestingly, this studies are all performed in Asia [12,15,
22]. Selection bias and recall bias of the study population should be
considered when explained these inconsistent results.
Of note, a study shows that rs699664 and rs12714145 are within a
region of strong linkage disequilibrium (LD) [9], however, rs11676382
is an unafﬁliated tagSNP with rs699664 [41], therefore, it is not
surprised that rs699664 and rs12714145 polymorphism showed the
same impact on warfarin dose requirement in overall analysis, and the
genetic variations of rs11676382 loci has a different impact on warfarin
dose requirement. In addition, this study found rs12714145 A carriers
showed different impact on warfarin dose compared to GG genotype
in Caucasian and Asian group, but not in rs699664.In fact, for thers12714145 SNP, only two studies for Caucasian and Asian popula-
tions respectively, rendering the analysis a lower statistical power,
therefore, the inconsistent results may be due to insufﬁcient studies
for rs12714145 SNP.
Considering racial background inﬂuencedwarfarin dosage,we carried
out a stratiﬁed analysis by ethnicity. The results indicated the impact of
rs11676382 polymorphismonwarfarin dose requirementmainly existed
in Caucasian. This difference, however, was not statistically signiﬁcance,
although there was similar trend, in Asian group, which indicates that
the effects of rs11676382 polymorphism on warfarin dose requirement
are different in ethnicities. In fact, the genotype and allele frequencies
of GGCX rs11676382 showed signiﬁcant difference among Asian and
Caucasian population in our systematic review, therefore, different
genetic backgrounds may contribute to the discrepancy. However, we
should notice that there are only two Asian studies in the analysis of
GGCX rs11676382, and limited studies and small sample sizes may lead
to insufﬁcient statistical power, therefore,we should carefully interpreted
the negative results. No signiﬁcant difference in the allele frequency of
rs699664 and rs12714145 SNPs between Asian and Caucasian, thus,
rs699664 and rs12714145 may not be the genetic factor attributing to
ethnic differences in warfarin dose.
The main determinant of warfarin dose adjustment is the value of
INR, while the racial background, such as genetic, cultural (diet related),
or both, is a determinant of warfarin dosage to maintain the target INR
[42]. After adjusted for confounding factors, Dang et al. [43] found that
all of the mean weekly warfarin doses were signiﬁcantly different in
Asians, Hispanics, Whites and African Americans, with a INR goal of 2
to 3.Therefore, the target INR ismainly inﬂuenced by ethnicity. Our sub-
group analysis further conﬁrmed this point, and it is possible to under-
stand the results of subgroup analysis according to themean target INR
were similar with stratiﬁed analysis by ethnicity. In addition, target INR
is also affected by age. The guidelines of the Japanese Circulation Society
for the treatment of nonvalvular atrial ﬁbrillation suggested that target
INR 2.0-3.0 is suitable for patients b70 years of age and lower intensity
with INR 1.6-2.6 for ⩾70 years of age [44]. However, our systematic
review found only one study with patients ⩾70 years of age [13], there-
fore, we did not further performed a stratiﬁed analysis by different age.
Due to different warfarin dose in different study populations, it is
understandable that signiﬁcant heterogeneity were observed in some
comparedmodels, however, any signiﬁcant change or revision inﬁndings
was also not found in sensitivity analysis, especially excluded the study
with low quality scores and small sample numbers. Taken together, we
believe our pooled analysis of the impact of GGCX genotype on warfarin
dose requirements are reliable.
Limitations and Perspectives
There are several limitations in our meta-analysis that need to
be considered when interpreting the results. First, as we know now,
VKORC1, CYP2C9, and CYP4F2 have been conﬁrmed as predictors of
warfarin dose requirement. Theoretically, the normalization procedure
used in our meta-analysis should remove any inﬂuences of VKORC1,
CYP2C9 and CYP4F2 genotype on the GGCX–warfarin dose association.
However, due to lack of original data from authors or studies that
746 Y. Sun et al. / Thrombosis Research 135 (2015) 739–747combine two or more of the above genes (i.e., the GGCX polymorphism
with one of the other 3 genes), this remains to be shown in future stud-
ies. Second, although thewarfarin dose effects of rs11676382 is demon-
strated, we should notice that the number of studies in patients of
rs11676382 SNPwas small (n= 5). It is possible that the lack of associ-
ation in the Asian group in rs11676382 SNP is related to insufﬁcient
studies. Therefore, the results need to be further conﬁrmed in larger
sample and different ethnicities. At last, previous studies most focus
on Asian and Caucasian populations, other ethnicity are need to further
investigate because our study indicates that the effects are different in
ethnicities.
In the past few years, the novel oral anticoagulants (NOACs), such as
Xa inhibitors rivaroxaban, apixaban, and edoxaban, have been approved
for clinical use. An advantage of the NOACs over warfarin is their stable
and consistent pharmacokinetics. However, despite being signiﬁcantly
more costly than warfarin (approximately $6–7 per day),it is difﬁcult
to ﬁnd an suitable antidote in the event of major bleeding using NOACS
[45]. For now, warfarin is still the most important anticoagulants, and
need for modeling more precise warfarin-dosing algorithms based on
pharmacogenomics.Conclusions
This is the ﬁrst meta-analysis about the impact of GGCX gene poly-
morphisms on warfarin dose requirements and the results showed
that GGCX rs11676382 polymorphismhave a signiﬁcant impact onwar-
farin dose requirements, especially in Caucasian populations. More and
larger studies inmultiethnic population are expected to be published on
this topic in the future, as it remains a topic of concern and interest.Conﬂict of Interest
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